Adam, J.

Besse, B.

Dziadziuszko, R.

Hasan, B.

Lacombe, D.A.

Lacroix, L.

Menis, J.

O'Brien, M.

Peters, S.

Stahel, R.A.

RERO DOC Digital Library

advanced NSCLC143TiP SPECTALUNG: SCREENING PATIENTSWITH THORACICTUMORS FOR EFFICIENT CLINICALTRIAL ACCESSB. Besse1, J. Menis2, J. Adam3, R. Dziadziuszko4, B. Hasan5, L. Lacroix6,S. Peters7, D.A. Lacombe8, M. O’Brien9, R.A. Stahel101Department of Cancer Medicine, Gustave Roussy Cancer Campus Grand Paris,Villejuif, France2Medical Department, European Organization for Research and Treatment ofCancer (EORTC), Brussels, Belgium3Pathology Department, Gustave Roussy Cancer Campus Grand Paris, Villejuif,France4Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk,Poland5Statistical Department, European Organisation for Research and Treatment ofCancer (EORTC), Brussels, Belgium6Department of Medical Biology and Pathology, Translational research Laboratoryand Biobank (UMS3655 CNRS /US23 INSERM), Gustave Roussy CancerCampus Grand Paris, Villejuif, France7Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne,Switzerland8Medical, European Organisation for Research and Treatment of Cancer (EORTC),Brussels, Belgium9Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK10Clinic for Oncology, University Hospital Zuerich, Zurich, SwitzerlandBackground: SPECTAlung is a screening program of the European Organization forthe Research and Treatment of Cancer (EORTC) in collaboration with the EuropeanThoracic Oncology Platform (ETOP) for efficient clinical trial access for patients withthoracic tumors. Screening for molecular alteration is center/country dependent, andlimited to a small subset of genes. Running clinical trials in small subsets of patients ischallenging also because of lack of uniform testing program. SPECTAlung is the firstEuropean standardized, quality-assured molecular testing platform for thoracic tumorcharacterization with the overall goal of giving access to specifically targeteddownstream clinical trials.Trial design: After consenting, existing tumor tissue will be collected, centralized andprocessed according to defined international quality control standards at GustaveRoussy Biobank (Villejuif, Fr). Next Generation Sequencing (NGS) will be performedat Sanger Institute (Cambridge, UK) where a panel of 360 genes will be analyzed formutations, rearrangements and gene copy number. Eligible patients will be thosehaving a pathological diagnosis of any thoracic tumor (lung cancer, malignant pleural© European Society for Medical Oncology 2015. Published by Oxford University Press on behalf of the European Lung Cancer Conference (ELCC) 2015 organisers.All rights reserved. For permissions, please email: journals.permissions@oup.com.abstractsAnnals of Oncology 26 (Supplement 1): i29–i44, 2015doi:10.1093/annonc/mdv050.47

143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS

http://doc.rero.ch/record/293856/files/mdv050.47.pdf

143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS

Abstract

Similar works

Full text

Available Versions

RERO DOC Digital Library